The US FDA's lawyers likely will not be expecting a flurry of subpoenas once the new Democratic majority takes power in the House of Representatives.
Hearings focused on drug pricing are a certainty and will almost surely include FDA Commissioner Scott Gottlieb, given his involvement in the administration's blueprint to reduce prescription costs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?